人类癌症中非组蛋白的可逆乙酰化作用

Reversible Acetylation of Non-histone Proteins in Human Cancers.

作者信息

Feng Chunran, Zeng Yiqun, Prochownik Edward V, Jiang Congqin, Li Youjun

机构信息

Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.

Division of Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, The Department of Microbiology and Molecular Genetics, The Pittsburgh Liver Research Center and The Hillman Cancer Center of UPMC, The University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

出版信息

Results Probl Cell Differ. 2025;75:363-390. doi: 10.1007/978-3-031-91459-1_13.

DOI:10.1007/978-3-031-91459-1_13

PMID:40593217

Abstract

Over the last three decades, we have witnessed great progress in uncovering the scope of reversible acetylation of non-histone proteins and understanding its mechanisms and functional consequences. In this review, we summarize the histone acetyltransferases (HATs)/deacetylases (HDACs) and their inhibitors, focusing on the role of reversible acetylation modification of non-histone proteins in tumor development while also exploring the application of HAT and HDAC inhibitors in cancer therapy.

摘要

在过去三十年中，我们目睹了在揭示非组蛋白可逆乙酰化的范围、理解其机制及功能后果方面取得的巨大进展。在本综述中，我们总结了组蛋白乙酰转移酶（HATs）/去乙酰化酶（HDACs）及其抑制剂，重点关注非组蛋白可逆乙酰化修饰在肿瘤发生中的作用，同时也探讨HAT和HDAC抑制剂在癌症治疗中的应用。